Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add filters
Database
Language
Document Type
Year range
1.
Fazirsiran shows promise for liver disease in AAT.
Ray, Katrina.
Nat Rev Gastroenterol Hepatol ; 19(9): 556, 2022 09.
Article in English | MEDLINE | ID: covidwho-2016729

Subject(s)
Digestive System Diseases , Liver Diseases , Humans , Liver
2.
Positive phase III results for odevixibat for progressive familial intrahepatic cholestasis.
Ray, Katrina.
Nat Rev Gastroenterol Hepatol ; 19(9): 556, 2022 09.
Article in English | MEDLINE | ID: covidwho-2016728

Subject(s)
Benzodiazepines , Butyrates , Cholestasis, Intrahepatic , Benzodiazepines/therapeutic use , Butyrates/therapeutic use , Cholestasis, Intrahepatic/drug therapy , Humans
3.
Saliva - a new route for enteric viruses.
Ray, Katrina.
Nat Rev Gastroenterol Hepatol ; 19(9): 556, 2022 09.
Article in English | MEDLINE | ID: covidwho-2016726

Subject(s)
Enterovirus , Saliva , Humans
4.
No increased risk of acute liver injury after COVID-19 vaccination.
Ray, Katrina.
Nat Rev Gastroenterol Hepatol ; 19(9): 556, 2022 09.
Article in English | MEDLINE | ID: covidwho-1956405

Subject(s)
COVID-19 , COVID-19 Vaccines , Humans , Liver , Vaccination
5.
Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD.
Ray, Katrina.
Nat Rev Gastroenterol Hepatol ; 18(5): 286, 2021 05.
Article in English | MEDLINE | ID: covidwho-1387373

Subject(s)
COVID-19 , SARS-CoV-2 , Antibody Formation , Gastrointestinal Agents/therapeutic use , Humans , Infliximab/therapeutic use
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL